All In Biotech

Drug Trial Radar · NCT03910660

A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype

A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC) or Adenocarcinoma Phenotype

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

97

Actual

Start

Jun 10, 2019

Primary completion

Oct 31, 2023

Study completion Aug 31, 2025

Sponsor

Lead sponsor
BioXcel Therapeutics IncIndustry
Sponsor type
Industry
First posted
Apr 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, multicenter, Phase 1b/2 study to identify the recommended Phase 2 dose and assess the efficacy and safety of talabostat administered orally, as monotherapy and in combination with pembrolizumab, in participants with mCRPC. Participants enrolled in the Phase 2a portion of the study will have either SCNC (Cohort A) or adenocarcinoma phenotype (Cohort B), while the Phase 2b randomized portion of the study will enroll only the histologic subtype(s) showing preliminary evidence in Phase 2a. The study will also assess other efficacy parameters, such as radiographic progression-free survival (rPFS), prostate-specific antigen progression-free survival (PSA PFS), overall survival (OS), and duration of response (DOR), as well as the safety of the combined treatment.

Conditions

  • Prostate Cancer
  • Neuroendocrine Tumors
  • Small Cell Carcinoma

Interventions

  • TalabostatDrug

    Oral Tablets

  • PembrolizumabDrug

    Intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2a: Composite Response Rate (CRR)Time frame: Up to approximately 4 years and 4 months
  2. Phase 2b: Objective Response Rate (ORR)Time frame: Up to approximately 4 years and 4 months

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California San Francisco (UCSF)

    San Francisco, California

  • BioXcel Clinical Research Site

    Denver, Colorado

  • Yale University

    New Haven, Connecticut

  • Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • BioXcel Clinical Research Site

    Detroit, Michigan

  • Center for Advanced Medicine / R.J. Zuckerberg Cancer Center (Northwell Health Cancer Institute)

    Lake Success, New York

  • Weill Cornell Medicine New York

    New York, New York

  • White Plains Hospital Center for Cancer Care

    White Plains, New York

  • The Ohio State University

    Columbus, Ohio

  • BioXcel Clinical Research Site

    Glasgow, England, United Kingdom

  • BioXcel Clinical Research Site

    London, Great Britain, United Kingdom

  • BioXcel Clinical Research Site

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.